Illimis Therapeutics is a biotechnology company focused on developing innovative treatments for challenging cancers, Alzheimer's, and immune diseases. Leveraging its proprietary GAIA platform, the company aims to advance its drug development pipeline through strategic global partnerships, including collaborations with industry leaders like Lilly Catalyze360-ExploR&D.
Leadership & Board
Current Number of Employees29
Current LinkedIn Followers642
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$42M
Total Amount Raised$42M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$42M
Latest Funding Amount$42M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Illimis Therapeutics had 29 employees as of October 12, 2026. The number of employees increased by 1 (3.57%) week-over-week.
29Latest Employee Count
1(3.57%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Illimis Therapeutics had 642 followers as of October 12, 2026. The number of followers increased by 5 (0.78%) week-over-week.
642Latest Followers Count
5(0.78%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.